6α,9α-Difluoro-11β,21-dihydroxy-16α,17α-[2-(2-oxo-tetrahydrofuran-3-yl)sulfanyl]ethylidenedioxy-pregn-4-ene-3,20-dione | 219720-01-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 6α,9α-Difluoro-11β,21-dihydroxy-16α,17α-[2-(2-oxo-tetrahydrofuran-3-yl)sulfanyl]ethylidenedioxy-pregn-4-ene-3,20-dione
• 英文别名: (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-[(2-oxooxolan-3-yl)sulfanylmethyl]-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
• CAS: 219720-01-1
• 化学式: C₂₇H₃₄F₂O₈S
• 分子量: 556.625
• InChiKey: YNIDWKOAMLWLNJ-SYZUQBDRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  38
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  145
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• COMPOUNDS
  申请人：——

  公开号：US20020019378A1

  公开（公告）日：2002-02-14

  A vane pump comprising a central shaft adapted to receive a rotational force from the outside, a ring gear formed in a hollow portion provided in the shaft, a linear gear formed on one end of a constant velocity coupling and meshed with the ring gear, and a ring gear formed in a hollow portion of an inner rotor and meshed with a linear gear formed on the other end of the constant velocity coupling, whereby it is rendered possible to rotate the shaft and inner rotor at an equal speed, insert a circular portion formed at one end of a vane into a circular hollow space of the inner rotor, bring the other end of the vane into contact with an inner surface of an outer rotor, and vary the volumes of a compression chamber and a supply chamber, the air being thereby compressed, so that high-pressure compressed air can be obtained by a small-volume vane pump without encountering the collision of parts causative of noise.

  一种叶片泵，包括一个中央轴，适用于从外部接收旋转力，轴上设有一个空心部分中形成的环齿，一个线性齿轮形成在恒速联轴器的一端，并与环齿啮合，一个环齿形成在内转子的空心部分中，并与恒速联轴器的另一端形成的线性齿轮啮合，从而使得轴和内转子能够以相同的速度旋转，将一个叶片的一端形成的圆形部分插入内转子的圆形空心空间中，将叶片的另一端与外转子的内表面接触，改变压缩腔和供给腔的容积，从而压缩空气，使得可以通过小体积叶片泵获得高压压缩空气，而不会遇到产生噪音的零部件碰撞。
• Compounds
  申请人：Angell Martyn Richard

  公开号：US20050070515A1

  公开（公告）日：2005-03-31

  Compounds capable of providing a therapeutic effect at a target site within a human or animal body with reduced systemic potency to said body are identified by comparing the susceptibility to hydrolysis of the compound in the presence of a purified lactonase enzyme or a recombinant form of it to the corresponding susceptibility in the absence of said lactonase enzyme, and then selecting a compound on the basis of enhanced susceptibility to hydrolysis in the presence of said lactonase enzyme

  通过比较纯化的内酰环酶酶或其重组形式存在时化合物的水解敏感性与不存在时的相应敏感性，来确定在人或动物体内的目标部位提供治疗效果且对该体系的系统效能降低的化合物，然后根据在内酰环酶酶存在时增强水解敏感性的基础上选择化合物。
• THARAPEUTICALLY ACTIVE COMPOUNDS WITH LOW SYSTEMIC ACTIVITY DUE TO REDUCED HALF-LIFE
  申请人：GLAXO GROUP LIMITED

  公开号：EP0998484A1

  公开（公告）日：2000-05-10
• METHOD OF IDENTIFYING COMPOUNDS HAVING REDUCED SYSTEMIC EFFECTS
  申请人：GLAXO GROUP LIMITED

  公开号：EP0998484B1

  公开（公告）日：2004-03-03
• [EN] COMPOUNDS<br/>[FR] COMPOSES
  申请人：——

  公开号：WO1999001467A2

  公开（公告）日：1999-01-14

  [EN] There are described therapeutically active compounds or salts or solvates thereof, hydrolysable in human or animal blood to compounds with reduced therapeutic activity. There is also described a method of identifying a compound capable of providing a therapeutic effect at a target site within a human or animal body with reduced systemic potency to said body comprising evaluating the half-life of said compound in the presence of human serum paraoxonase. Suitable compounds have a half-life of less than 1 hour.
  [FR] L'invention concerne des composés, sels ou solvates de ceux-ci, actifs sur le plan thérapeutique, et qui peuvent s'hydrolyser dans le sang humain ou animal pour donner des composés possédant une activité thérapeutique réduite. L'invention concerne également un procédé d'identification d'un composé pouvant produire un effet thérapeutique au niveau d'un site cible, dans un corps humain ou animal, et possédant des effets secondaires réduits dans ce corps, ce procédé consistant à évaluer la demi-vie du composé en présence d'une paraoxonase sérique humaine. Des composés appropriés possèdent une demi-vie inférieure à une heure.